DOCSLIB.ORG

Targets and Mechanisms Validated Trials on the Horizon Targets And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targets and Mechanisms Validated Trials on the Horizon Targets And TargetsTargets and and Mechanisms Mechanisms Validated Validated TrialsTrials on on the the Horizon Horizon Research Investors Report 2011 TABLE OF CONTENTS Huntington’s Disease Research in 2011: Targets and Mechanisms Validated; Trials on the Horizon FINDING AND VALIDATING TARGETS 4 DRP1 4 Ku705 5 A CLOSER LOOK AT THE HD PROTEIN 6 HR Protein aggregates visualized 6 Form of the HD protein associated with neurodegeneration identified 7 DISCOVERING/DEVELOPING NEW DRUGS AND UNDERSTANDING THEIR MECHANISMS 10 Dantrolene appears to be neuroprotective 10 Melatonin delays onset and prolongs survival in the R6/2 Mouse 11 KMO Inhibitor developed 12 New Caspase Inhibitors identified and Optimized 14 Quinazoline derivative looks promising 15 Phosphodiesterase-10 inhibitors 16 Novel benzoxazine compounds may be neuroprotective 18 Dimethylfumarate is helpful to the YAC128 Mouse 18 IPSC Consortium creates stem cell lines 19 FINDING AND VALIDATING BIOMARKERS 21 H2AFY 21 Protein Aggregates 22 TRACK-HD 22 UNDERSTANDING THE DISEASE COURSE AND IMPROVING CLINICAL MEASURES 25 Progression of HD and MRI imaging 25 Enroll-HD 25 POTENTIAL TREATMENTS MOVING CLOSE TO CLINICAL TRIALS 27 RNAi Primate Study 27 ASOs can be made allele specific 27 Mesenchymal stem cells with BDNF 28 CLINICAL TRIALS 30 Lessons from Dimebon 30 Neurosearch -- Huntexil (ACR-16) 31 Prana Biotech Copper Chelator 31 Siena Biotech Sirt1 Inhibitor 32 THE OTHER MEMBERS OF THE RESEARCH TEAM - THE PARTICIPANTS 33 FINAL THOUGHTS 35 HD DRUG DEVELOPMENT PIPELINE CHART 36 HDSA COALITION FOR THE CURE 37 HDSA CENTERS OF EXCELLENCE 38 Cover Photo: Polarizing optical microscopy image of huntingtin peptide aggregates stained with Congo Red. Courtesy of Dr. Christopher Stanley, Neutron Scattering Science Division, Oak Ridge National Laboratory. Targets and Mechanisms Validated: Trials on the Horizon 2 Research Investors Report 2011 RESEARCH INVESTORS’ REPORT 2011 Targets and Mechanisms Validated: Clinical Trials on the Horizon he year 2011 was a very fertile one for Huntington’s disease research. The exciting prospect Tof gene silencing worked its way through to testing in primates; we were able to actually see protein aggregation at its earliest and most toxic stages; many new potential therapeutic target pathways were identified; several biomarker candidates that will allow the measurement of effectiveness of future therapeutics were brought close to validation; and a number of new drugs were added to the HD pipeline of potential treatments based on research which focused on both effectiveness and the mechanism of action. New developments were announced almost weekly. Some of the major findings included in this report were published less than two weeks before it was completed. Last year we reported on a growing pipeline of potential treatments that either target the expression of the gene or one of a variety of pathogenic processes. Researchers whom HDSA has been funding for many years have been key to the effort to move treatments from the lab to the clinic through their leadership in discovering targets, developing drugs, and providing support for translational efforts that led to clinical trials. As an illustration of how critical your donations to HDSA research has been to the progress we’re seeing today, we’ve color-coded (in blue) names of members of the HDSA Coalition for the Cure, and other scientists who have received Grants or Fellowships from HDSA as well. As the pipeline has grown, it has become increasingly clear that we need to maximize the probability that clinical trials will be successful. Giving priority to those drugs with a validated target and a known mechanism, finding biomarkers, and improving clinical measures are ways to accomplish this goal. This year we have seen major progress in research directed to these areas with scientists doing careful work to find and validate targets, develop drugs which address those targets, and understand the mechanism involved in potential treatments. There are new drugs in development and new clinical trials on the horizon. HDSA continues to focus on the need to educate people about potential treatments and the importance of observational and clinical trials so that members of the community can make informed decisions about how to participate in efforts to evaluate potential therapies for FDA approval. Targets and Mechanisms Validated: Trials on the Horizon 3 Research Investors Report 2011 Finding and Validating Targets Researchers are using multiple research methods and models of Huntington’s disease to find and validate targets. DRP1 is Identified as a Promising Therapeutic Target Impaired energy metabolism has been identified as a major pathology in Huntington’s disease. As work by Dr. Marcy MacDonald, Massachusetts General Hospital and Harvard Medical School, has shown, mitochondria, the cell’s energy factories, are not intrinsically defective but are thought to be mismanaged in some way in HD. A University of Central Florida research team lead by Dr. Ella Bossy-Wetzel has discovered how this occurs. The HD protein interacts abnormally with the mitochondrial fission GTPase dynamin-related protein-1 (DRP1). DRP1 is the protein that is responsible for mitochondria fission in the fission-fusion cycle1. DRP1 becomes overactive and upsets the balance in the cycle. The mitochondria fragment, mitochondrial transport becomes impaired, and cells die. The researchers used multiple models and techniques to understand and confirm the role of DRP1. They first examined rat cortical cells. Those with a normal polyglutamine region had healthy mitochondria whereas those with expanded polyglutamine stretches (expanded CAG repeats) had fragmented mitochondria. Those with 97 CAG repeats had more fragmentation than those with 46 CAG repeats. Time lapse imaging showed an increase of fission events compared to fusion events. Fragmentation was correlated with cell death. Dr. Bossy-Wetzel and colleague examines rat cortical cells Human skin cells were next examined. Fragmentation was also found in cells from people with Huntington’s disease, more so in those with juvenile rather than adult onset. In addition, the researchers also examined mitochondrial transport and velocity in rat cortical cells. Transport and velocity were normal when the CAG repeats were normal but decreased with expanded repeats. Again, the impairment was more severe with higher repeats. This is important because decreased transport would likely have a negative effect on energy distribution especially at synapses where demand for energy is high. The researchers confirmed their findings in the YAC1282 mice, finding an increase in mitochondrial fragmentation before the onset of symptoms, neurological deficits, aggregate formation, and cell death. 1. Fission-Fusion Cycle -- In recent years it has been discovered that individual mitochondria do not exist as permanently distinct entities as was previously believed but instead form a dynamic network within which proteins, lipids and mitochondrial DNA are exchanged by rapid divisions and fusions. The reason for this is not clear but it has been speculated that this is a method which evolved to combat the accumulation of mitochondrial DNA mutations. Targets and Mechanisms Validated: Trials on the Horizon 4 Research Investors Report 2011 The researchers next examined the possible role of DRP1 in fragmentation. Examining both the YAC128 mice and human brain tissue, they found that while the normal huntingtin protein only weakly interacts with DRP1 at best, the HD protein binds to DRP1 and increases its enzymatic activity. Finally, they found that restoring the normal fission-fusion cycle by replacing DRP1 with a mutant version (DRP1 K38A) which promotes fusion, they were able to rescue the cell from mitochondrial fragmentation, mitochondrial transport impairment, and cell death. More work is planned to explore whether this finding can be translated into a treatment. Ku70: a regulatory factor for DNArepair proposed as a therapeutic target A team of Japanese scientists and Dr. Erich Wanker, Max Delbruck Center for Molecular Medicine, Berlin, Germany, have identified Ku70 as a new therapeutic target in Huntington’s disease. Ku70 is a critical protein involved in DNA double strand break (DSB) repair. In previous research, they found that the HD protein directly interacts with and impairs Ku70 and that restoring Ku70 increases the survival time of the R6/2 mice. Dr. Erich Wanker Working with several different drosophila models of HD in this study, they found that Ku70 co-expression reverses shortened lifespan, impaired motor activity and eye degeneration. In contrast, Ku70 reduction makes these HD caused pathologies more severe. The authors conclude that their research provides a rationale for targeting Ku70. They plan to proceed with translational efforts, either using viral vectors to express Ku70 or developing a drug that would mimic Ku70’s affect on double strand DNA breaks. 2. YAC128 Mouse – a mouse model of Huntington’s disease that expresses the full-length human HD gene with 128 CAG repeats. The model closely replicates the slow progression of behavioral deficits and striatal neuronal loss characteristic of the human disease. Targets and Mechanisms Validated: Trials on the Horizon 5 Research Investors Report 2011 A Closer Look at the HD Protein The Huntington’s disease protein is a major target because it causes the disease, but it is not fully understood. This year, researchers have made some major advances in understanding the nature
Load more

Recommended publications
  • Structure-Based Redesigning of Pentoxifylline Analogs Against
    www.nature.com/scientificreports OPEN Structure‑based redesigning of pentoxifylline analogs against selective phosphodiesterases to modulate sperm functional competence for assisted reproductive technologies Mutyala Satish1,5, Sandhya Kumari2,5, Waghela Deeksha1, Suman Abhishek1, Kulhar Nitin1, Satish Kumar Adiga2, Padmaraj Hegde3, Jagadeesh Prasad Dasappa4, Guruprasad Kalthur2* & Eerappa Rajakumara1* Phosphodiesterase (PDE) inhibitors, such as pentoxifylline (PTX), are used as pharmacological agents to enhance sperm motility in assisted reproductive technology (ART), mainly to aid the selection of viable sperm in asthenozoospermic ejaculates and testicular spermatozoa, prior to intracytoplasmic sperm injection (ICSI). However, PTX is reported to induce premature acrosome reaction (AR) and, exert toxic efects on oocyte function and early embryo development. Additionally, in vitro binding studies as well as computational binding free energy (ΔGbind) suggest that PTX exhibits weak binding to sperm PDEs, indicating room for improvement. Aiming to reduce the adverse efects and to enhance the sperm motility, we designed and studied PTX analogues. Using structure‑guided in silico approach and by considering the physico‑chemical properties of the binding pocket of the PDEs, designed analogues of PTX. In silico assessments indicated that PTX analogues bind more tightly to PDEs and form stable complexes. Particularly, ex vivo evaluation of sperm treated with one of the PTX analogues (PTXm‑1), showed comparable benefcial efect at much lower concentration—slower
    [Show full text]
  • Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopa
    The Journal of Neuroscience, June 15, 2002, 22(12):5188–5197 Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning Tracy M. Reed,1,3 David R. Repaske,2* Gretchen L. Snyder,4 Paul Greengard,4 and Charles V. Vorhees1* Divisions of 1Developmental Biology and 2Endocrinology, Children’s Hospital Research Foundation, Cincinnati, Ohio 45229, 3Department of Biology, College of Mount St. Joseph, Cincinnati, Ohio 45233, and 4Laboratory of Molecular and Cellular Neuroscience, Rockefeller University, New York, New York 10021 Using homologous recombination, we generated mice lack- maze spatial-learning deficits. These results indicate that en- ing phosphodiesterase-mediated (PDE1B) cyclic nucleotide- hancement of cyclic nucleotide signaling by inactivation of hydrolyzing activity. PDE1B Ϫ/Ϫ mice showed exaggerated PDE1B-mediated cyclic nucleotide hydrolysis plays a signifi- hyperactivity after acute D-methamphetamine administra- cant role in dopaminergic function through the DARPP-32 and tion. Striatal slices from PDE1B Ϫ/Ϫ mice exhibited increased related transduction pathways. levels of phospho-Thr 34 DARPP-32 and phospho-Ser 845 Key words: phosphodiesterases; DARPP-32; dopamine- GluR1 after dopamine D1 receptor agonist or forskolin stimu- stimulated locomotor activity; spatial learning and memory; lation. PDE1B Ϫ/Ϫ and PDE1B ϩ/Ϫ mice demonstrated Morris Morris water maze; methamphetamine; SKF81297; forskolin Calcium/calmodulin-dependent phosphodiesterases (CaM- (CaMKII) and calcineurin and have the potential to activate PDEs) are members of one of 11 families of PDEs (Soderling et CaM-PDEs. Dopamine D1 or D2 receptor activation leads to al., 1999;Yuasa et al., 2001) and comprise the only family that acts adenylyl cyclase activation or inhibition, respectively (Traficante ϩ as a potential point of interaction between the Ca 2 and cyclic et al., 1976; Monsma et al., 1990; Cunningham and Kelley, 1993; nucleotide signaling pathways.
    [Show full text]
  • The Rational Search for PDE10A Inhibitors from Sophora Flavescens Roots Using Pharmacophore‑ and Docking‑Based Virtual Screening
    388 MOLECULAR MEDICINE REPORTS 17: 388-393, 2018 The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening HAN-TIAN FAN1, JUN-FANG GUO1, YU-XIN ZHANG2, YU-XI GU1, ZHONG-QI NING1, YAN-JIANG QIAO2 and XING WANG1,3 1School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069; 2Key Laboratory of TCM-Information Engineer of State Administration of TCM, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102; 3Beijing Key Laboratory of Traditional Chinese Medicine (TCM) Collateral Disease Theory Research, Capital Medical University, Beijing 100069, P.R. China Received May 27, 2017; Accepted August 31, 2017 DOI: 10.3892/mmr.2017.7871 Abstract. Phosphodiesterase 10A (PDE10A) has been Introduction confirmed to be an important target for the treatment of central nervous system (CNS) disorders. The purpose of the Phosphodiesterases (PDEs) are a family of enzymes that are present study was to identify PDE10A inhibitors from herbs able to lyse phosphodiester bonds, are expressed widely, and used in traditional Chinese medicine. Pharmacophore and have demonstrable clinical significance (1,2). PDE10A has molecular docking techniques were used to virtually screen been demonstrated to be a potential target for the treatment the chemical molecule database of Sophora flavescens, a of central nervous system (CNS) disorders (3,4). Previous well-known Chinese herb that has been used for improving studies have confirmed that PDE10A inhibitors have impor- mental health and regulating the CNS. The pharmacophore tant biological activity in the treatment of psychosis (5-7). model generated recognized the common functional groups of Therefore, screening for PDE10A inhibitors is an effective known PDE10A inhibitors.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-321,2,3
    New Research Disorders of the Nervous System Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-321,2,3 Marina Polito,1,2 Elvire Guiot,1,2 Giuseppe Gangarossa,3,4,5 Sophie Longueville,2,6,7 Mohamed Doulazmi,1,2 Emmanuel Valjent,3,4 Denis Hervé,2,6,7 Jean-Antoine Girault,2,6,7 Danièle Paupardin-Tritsch,1,2 Liliana R. V. Castro,1,2 and Pierre Vincent1,2 DOI:http://dx.doi.org/10.1523/ENEURO.0060-15.2015 1CNRS, UMR8256 “Biological Adaptation and Ageing”, Institut de Biologie Paris-Seine (IBPS), F-75005 Paris, France, 2Université Pierre et Marie Curie (UPMC, Paris 6), Sorbonne Universités, Paris, F-75005, France, 3CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier, F-34094, France, 4Institut National de la Santé et de la Recherche Médicale, U661, Montpellier, F-34094, France, 5Universités de Montpellier 1 & 2, UMR-5203, Montpellier, F-34094, France, 6Institut National de la Santé et de la Recherche Médicale UMR-S 839, Paris, France, and 7Institut du Fer a` Moulin, Paris, France Abstract Type 10A phosphodiesterase (PDE10A) is highly expressed in the striatum, in striatonigral and striatopallidal medium- sized spiny neurons (MSNs), which express D1 and D2 dopamine receptors, respectively. PDE10A inhibitors have pharmacological and behavioral effects suggesting an antipsychotic profile, but the cellular bases of these effects are unclear. We analyzed the effects of PDE10A inhibition in vivo by immunohistochemistry, and imaged cAMP, cAMP- dependent protein kinase A (PKA), and cGMP signals with biosensors in mouse brain slices. PDE10A inhibition in mouse striatal slices produced a steady-state increase in intracellular cAMP concentration in D1 and D2 MSNs, demonstrating that PDE10A regulates basal cAMP levels.
    [Show full text]
  • I STRUCTURE and FUNCTION of the PALMITOYLTRANSFERASE
    STRUCTURE AND FUNCTION OF THE PALMITOYLTRANSFERASE DHHC20 AND THE ACYL COA HYDROLASE MBLAC2 A Dissertation Presented to the Faculty of the Graduate School Of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy By Martin Ian Paguio Malgapo December 2019 i © 2019 Martin Ian Paguio Malgapo ii STRUCTURE AND FUNCTION OF THE PALMITOYLTRANSFERASE DHHC20 AND THE ACYL COA HYDROLASE MBLAC2 Martin Ian Paguio Malgapo, Ph.D. Cornell University 2019 My graduate research has focused on the enzymology of protein S-palmitoylation, a reversible posttranslational modification catalyzed by DHHC palmitoyltransferases. When I started my thesis work, the structure of DHHC proteins was not known. I sought to purify and crystallize a DHHC protein, identifying DHHC20 as the best target. While working on this project, I came across a protein of unknown function called metallo-β-lactamase domain-containing protein 2 (MBLAC2). A proteomic screen utilizing affinity capture mass spectrometry suggested an interaction between MBLAC2 (bait) and DHHC20 (hit) in HEK-293 cells. This finding interested me initially from the perspective of finding an interactor that could help stabilize DHHC20 into forming better quality crystals as well as discovering a novel protein substrate for DHHC20. I was intrigued by MBLAC2 upon learning that this protein is predicted to be palmitoylated by multiple proteomic screens. Additionally, sequence analysis predicts MBLAC2 to have thioesterase activity. Taken together, studying a potential new thioesterase that is itself palmitoylated was deemed to be a worthwhile project. When the structure of DHHC20 was published in 2017, I decided to switch my efforts to characterizing MBLAC2.
    [Show full text]
  • Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes
    Biosci. Biotechnol. Biochem., 77 (3), 566–571, 2013 Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes y Tomoji ONO,1;2; Chikako FUJISAKI,1 Yasuharu ISHIHARA,1 Keiko IKOMA,1;2 Satoru MORISHITA,1;3 Michiaki MURAKOSHI,1;4 Keikichi SUGIYAMA,1;5 Hisanori KATO,3 Kazuo MIYASHITA,6 Toshihide YOSHIDA,4;7 and Hoyoku NISHINO4;5 1Research and Development Headquarters, Lion Corporation, 100 Tajima, Odawara, Kanagawa 256-0811, Japan 2Department of Supramolecular Biology, Graduate School of Nanobioscience, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan 3Food for Life, Organization for Interdisciplinary Research Projects, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan 4Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto 602-8566, Japan 5Research Organization of Science and Engineering, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan 6Department of Marine Bioresources Chemistry, Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minatocho, Hakodate, Hokkaido 041-8611, Japan 7Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyou-ku, Kyoto 604-8845, Japan Received October 22, 2012; Accepted November 26, 2012; Online Publication, March 7, 2013 [doi:10.1271/bbb.120817] Lactoferrin (LF) is a multifunctional glycoprotein resistance, high blood pressure, and dyslipidemia. To found in mammalian milk. We have shown in a previous prevent progression of metabolic syndrome, lifestyle clinical study that enteric-coated bovine LF tablets habits must be improved to achieve a balance between decreased visceral fat accumulation. To address the energy intake and consumption. In addition, the use of underlying mechanism, we conducted in vitro studies specific food factors as helpful supplements is attracting and revealed the anti-adipogenic action of LF in pre- increasing attention.
    [Show full text]
  • Phosphodiesterase 4B: Master Regulator of Brain Signaling
    cells Review Phosphodiesterase 4B: Master Regulator of Brain Signaling Amy J. Tibbo and George S. Baillie * Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)141-330-1662 Received: 3 February 2020; Accepted: 14 May 2020; Published: 19 May 2020 Abstract: Phosphodiesterases (PDEs) are the only superfamily of enzymes that have the ability to break down cyclic nucleotides and, as such, they have a pivotal role in neurological disease and brain development. PDEs have a modular structure that allows targeting of individual isoforms to discrete brain locations and it is often the location of a PDE that shapes its cellular function. Many of the eleven different families of PDEs have been associated with specific diseases. However, we evaluate the evidence, which suggests the activity from a sub-family of the PDE4 family, namely PDE4B, underpins a range of important functions in the brain that positions the PDE4B enzymes as a therapeutic target for a diverse collection of indications, such as, schizophrenia, neuroinflammation, and cognitive function. Keywords: phosphodiesterase; cyclic-AMP; rolipram; PDE4B; neuroinflammation 1. Introduction Cyclic nucleotides are ubiquitous signaling molecules that are recognized as archetypal second messengers. Since their discovery, there has been an unprecedented drive to understand signal transduction systems that utilize them and to characterize physiological systems under their control. It is well established that both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling systems underpin critical pathways necessary for brain development and function [1–4].
    [Show full text]
  • Downregulation of Carnitine Acyl-Carnitine Translocase by Mirnas
    Page 1 of 288 Diabetes 1 Downregulation of Carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion Mufaddal S. Soni1, Mary E. Rabaglia1, Sushant Bhatnagar1, Jin Shang2, Olga Ilkayeva3, Randall Mynatt4, Yun-Ping Zhou2, Eric E. Schadt6, Nancy A.Thornberry2, Deborah M. Muoio5, Mark P. Keller1 and Alan D. Attie1 From the 1Department of Biochemistry, University of Wisconsin, Madison, Wisconsin; 2Department of Metabolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey; 3Sarah W. Stedman Nutrition and Metabolism Center, Duke Institute of Molecular Physiology, 5Departments of Medicine and Pharmacology and Cancer Biology, Durham, North Carolina. 4Pennington Biomedical Research Center, Louisiana State University system, Baton Rouge, Louisiana; 6Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, New York, New York. Corresponding author Alan D. Attie, 543A Biochemistry Addition, 433 Babcock Drive, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, (608) 262-1372 (Ph), (608) 263-9608 (fax), [email protected]. Running Title: Fatty acyl-carnitines enhance insulin secretion Abstract word count: 163 Main text Word count: 3960 Number of tables: 0 Number of figures: 5 Diabetes Publish Ahead of Print, published online June 26, 2014 Diabetes Page 2 of 288 2 ABSTRACT We previously demonstrated that micro-RNAs 132 and 212 are differentially upregulated in response to obesity in two mouse strains that differ in their susceptibility to obesity-induced diabetes. Here we show the overexpression of micro-RNAs 132 and 212 enhances insulin secretion (IS) in response to glucose and other secretagogues including non-fuel stimuli. We determined that carnitine acyl-carnitine translocase (CACT, Slc25a20) is a direct target of these miRNAs.
    [Show full text]
  • Tracking Brain Palmitoylation Change: Predominance of Glial Change in a Mouse Model of Huntington’S Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Chemistry & Biology Resource Tracking Brain Palmitoylation Change: Predominance of Glial Change in a Mouse Model of Huntington’s Disease Junmei Wan,1,4 Jeffrey N. Savas,2,4 Amy F. Roth,1 Shaun S. Sanders,3 Roshni R. Singaraja,3,5 Michael R. Hayden,3 John R. Yates III,2 and Nicholas G. Davis1,* 1Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA 2Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA 3Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada 4These authors contributed equally to this work 5Present address: Translational Laboratory in Genetic Medicine, Department of Medicine, National University of Singapore, and Agency for Science, Technology and Research, 8A Biomedical Grove, Singapore 138648, Singapore *Correspondence: [email protected] http://dx.doi.org/10.1016/j.chembiol.2013.09.018 SUMMARY a number of neurological disorders, notably in schizophrenia and mental retardation, as well as in Huntington’s disease (HD) Protein palmitoylation, a reversible lipid modification and Alzheimer disease (Young et al., 2012). Below, we describe of proteins, is widely used in the nervous system, ABE/SILAM, a proteomic strategy that profiles and quantifies with dysregulated palmitoylation being implicated brain palmitoylation change within
    [Show full text]
  • Potential Therapeutic Agents for Glioblastoma
    pharmaceuticals Concept Paper Methylxanthines: Potential Therapeutic Agents for Glioblastoma Daniel Pérez-Pérez 1,2 , Iannel Reyes-Vidal 2 , Elda Georgina Chávez-Cortez 2 , Julio Sotelo 2 and Roxana Magaña-Maldonado 2,* 1 PECEM, Faculty of Medicine, National Autonomous University of México, México City 04510, Mexico 2 Neuroimmunology and Neuro-oncology Unit, National Institute of Neurology and Neurosurgery, México City 14269, Mexico * Correspondence: [email protected]; Tel.: +52-55-5606-4040 Received: 5 July 2019; Accepted: 1 September 2019; Published: 7 September 2019 Abstract: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells. One of these pathways is the deregulation of phosphodiesterases (PDEs). These enzymes participate in the development of GBM and may have value as therapeutic targets to treat GBM. Methylxanthines (MXTs) such as caffeine, theophylline, and theobromine are PDE inhibitors and constitute a promising therapeutic anti-cancer agent against GBM. MTXs also regulate various cell processes such as proliferation, migration, cell death, and differentiation; these processes are related to cancer progression, making MXTs potential therapeutic agents in GBM. Keywords: brain tumors; natural alkaloids; drug repositioning 1. Introduction Glioblastoma (GBM) is the most aggressive and most frequent primary malignant tumor of the central nervous system (CNS) [1]. It occurs more frequently in men and in people older than 55 years [2]. Pathological characteristics of GBM include cellular heterogeneity, angiogenesis, high proliferation rate, and increased migratory capacity [3].
    [Show full text]